Everything on the page, in the order a chemist would read it
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
Independent testing
Page 10 of 27 of this archive, newest first.
Independent analysis puts a CPC orforglipron lot at 95.3%, against 92.5% on the certificate
The result is unremarkable. What the report omits is not.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Why Medutest can tell you the mass is right and not that the sequence is
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
Medutest result on a Shanghai mazdutide lot lands 1.2 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Medutest result on a Tianjin tirzepatide lot lands 4.3 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Independent analysis puts a WWB exenatide lot at 97.8%, against 95.3% on the certificate
The result is unremarkable. What the report omits is not.
What VendorInvestigate would need in order to certify sterility, and why it does not
We asked all four services what they can determine, on what timescale, at what price, and under what accreditation. The answers are printed in full.
Janoshik result on a Chengdu cagrilintide lot lands 1.8 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Independent analysis puts a GL Biochem exenatide lot at 96.5%, against 93.6% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
VendorInvestigate result on a Shenzhen dulaglutide lot lands 2.0 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Where the solvent front ends is a decision, not a fact
The denominator excludes solvent-front features and injection artefacts by convention. Conventions differ on where the front ends, and a fragment eluting early exists in one…
Who chose the vial that was tested?
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
VendorInvestigate result on a Wuhan mazdutide lot lands 3.4 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
We asked four laboratories for a sterility test. Here is what came back.
A compendial sterility test takes fourteen days of incubation and consumes the containers tested. That timescale is incompatible with the business model that made…
Independent analysis puts a QSC liraglutide lot at 99.2%, against 97.6% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Independent analysis puts a GL Biochem liraglutide lot at 96.0%, against 93.9% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
Sterility is not a percentage, which is the whole difficulty
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure
We submitted vials for endotoxin determination and report the results, the method and the laboratory, because a pyrogen figure without a method is as empty as a purity…
Medutest result on a Qingdao orforglipron lot lands 0.8 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.